This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
As Americans prepare for holiday travel amid a nationwide measles resurgence and diminished federal public health communications, a new report from the Center for Infectious Disease Research and Policy's (CIDRAP's) Vaccine Integrity Project (VIP) at the University of Minnesota highlights data showing that infants as young as 6 months can safely receive the measles, mumps and rubella (MMR) vaccine.
The United States has recorded more than 5,400 measles cases and 10 measles-related deaths across 45 states this year. Today, the Pan American Health Organization formally revoked the nation's measles elimination status, which it has held for more than 26 years. Loss of measles elimination status signals that the virus has been spreading in one continuous chain for at least a year.
Routine MMR vaccination begins at 12 to 15 months, but for decades, federal health authorities and medical societies have recommended early measles vaccination, sometimes called a "zero dose," for eligible infants ages 6 to 11 months who will be traveling internationally or living in or traveling to areas experiencing active measles outbreaks.
Measles is particularly dangerous for infants because the protective antibodies they receive from their mothers wane during their first months of life.
"There are several critical reasons why we're emphasizing these recommendations now. First and foremost, the risk of measles exposure in the United States has changed dramatically," says CIDRAP director Michael T.
Source link







